Rituximab therapy in severe juvenile pemphigus vulgaris

Adam J. Mamelak, Mark P. Eid, Bernard A. Cohen, Grant J. Anhalt

Research output: Contribution to journalReview articlepeer-review

Abstract

Juvenile pemphigus vulgaris (PV) is a rare and often misdiagnosed condition. Although PV frequently is severe in children, a substantial portion of the morbidity and mortality associated with juvenile PV has been attributed to treatment. This report demonstrates the efficacy of rituximab therapy in juvenile PV. We report 2 cases and review the literature. Rituximab treatment was effective in helping to control 2 recalcitrant cases of juvenile PV without inducing the adverse effects associated with other adjuvant therapies. Rituximab should be considered when treating resistant cases of PV in pediatric populations to avoid the long-term side effects of other immunosuppressive treatments.

Original languageEnglish (US)
Pages (from-to)335-340
Number of pages6
JournalCutis
Volume80
Issue number4
StatePublished - Oct 2007

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Rituximab therapy in severe juvenile pemphigus vulgaris'. Together they form a unique fingerprint.

Cite this